- Home
- SONN vs QLGN Comparison
SONN vs QLGN Comparison
Compare SONN & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONN
- QLGN
- Stock Information
- Founded
- SONN N/A
- QLGN 1996
- Country
- SONN United States
- QLGN United States
- Employees
- SONN N/A
- QLGN N/A
- Industry
- SONN Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- SONN Health Care
- QLGN Health Care
- Exchange
- SONN Nasdaq
- QLGN Nasdaq
- Market Cap
- SONN 2.5M
- QLGN 2.9M
- IPO Year
- SONN N/A
- QLGN N/A
- Fundamental
- Price
- SONN $1.51
- QLGN $4.27
- Analyst Decision
- SONN Strong Buy
- QLGN
- Analyst Count
- SONN 2
- QLGN 0
- Target Price
- SONN $38.00
- QLGN N/A
- AVG Volume (30 Days)
- SONN 2.8M
- QLGN 32.0K
- Earning Date
- SONN 12-17-2024
- QLGN 11-14-2024
- Dividend Yield
- SONN N/A
- QLGN N/A
- EPS Growth
- SONN N/A
- QLGN N/A
- EPS
- SONN N/A
- QLGN N/A
- Revenue
- SONN $18,626.00
- QLGN N/A
- Revenue This Year
- SONN N/A
- QLGN N/A
- Revenue Next Year
- SONN N/A
- QLGN N/A
- P/E Ratio
- SONN N/A
- QLGN N/A
- Revenue Growth
- SONN N/A
- QLGN N/A
- 52 Week Low
- SONN $1.41
- QLGN $3.34
- 52 Week High
- SONN $18.72
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- SONN 26.27
- QLGN 47.55
- Support Level
- SONN $1.41
- QLGN $3.90
- Resistance Level
- SONN $1.94
- QLGN $4.16
- Average True Range (ATR)
- SONN 0.37
- QLGN 0.33
- MACD
- SONN 0.05
- QLGN 0.07
- Stochastic Oscillator
- SONN 2.91
- QLGN 64.12
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.